|
Amyotrophic Lateral Sclerosis
|
0.310 |
Biomarker
|
disease |
BEFREE |
Blocking DR6 function represents a new approach for the treatment of neurodegenerative disorders involving motor neuron death and axon degeneration, such as ALS.
|
24113175 |
2013 |
|
Amyotrophic Lateral Sclerosis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Blocking DR6 function represents a new approach for the treatment of neurodegenerative disorders involving motor neuron death and axon degeneration, such as ALS.
|
24113175 |
2013 |
|
Gliosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis.
|
24113175 |
2013 |
|
Amyotrophic Lateral Sclerosis With Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis.
|
24113175 |
2013 |
|
Amyotrophic Lateral Sclerosis, Guam Form
|
0.300 |
Biomarker
|
disease |
CTD_human |
Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis.
|
24113175 |
2013 |
|
Astrocytosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis.
|
24113175 |
2013 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB.
|
11753679 |
2001 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB.
|
11753679 |
2001 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Additional analysis of TCGA-data was performed to assess the general alteration of DR6 in cancer and influence of IDH-mutation on DR6 expression in gliomas.
|
31092421 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Additional analysis of TCGA-data was performed to assess the general alteration of DR6 in cancer and influence of IDH-mutation on DR6 expression in gliomas.
|
31092421 |
2019 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In the present study, our analysis of ovarian cancer RNA sequencing data from The Cancer Genome Atlas revealed that DR6 is upregulated in human ovarian cancer.
|
30186750 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In the present study, our analysis of ovarian cancer RNA sequencing data from The Cancer Genome Atlas revealed that DR6 is upregulated in human ovarian cancer.
|
30186750 |
2018 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Significant changes in the levels of protein and mRNA expression were detected, mainly in the death receptor 6 (Dr6) gene of patients suffering from cancer of the corpus and cervix uteri and ovarian cancer, which also corresponded with the level of protein Dr6.
|
25113253 |
2014 |
|
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Significant changes in the levels of protein and mRNA expression were detected, mainly in the death receptor 6 (Dr6) gene of patients suffering from cancer of the corpus and cervix uteri and ovarian cancer, which also corresponded with the level of protein Dr6.
|
25113253 |
2014 |
|
Astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.
|
31092421 |
2019 |
|
Mastitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three Novel Players: PTK2B, SYK, and TNFRSF21 Were Identified to Be Involved in the Regulation of Bovine Mastitis Susceptibility via GWAS and Post-transcriptional Analysis.
|
31447828 |
2019 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of DR6 is elevated in different kinds of tumors including ovarian, breast cancer and adult sarcoma.
|
31092421 |
2019 |
|
Sarcoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of DR6 is elevated in different kinds of tumors including ovarian, breast cancer and adult sarcoma.
|
31092421 |
2019 |
|
Malignant neoplasm of soft tissue
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of DR6 is elevated in different kinds of tumors including ovarian, breast cancer and adult sarcoma.
|
31092421 |
2019 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The expression of death receptor 6 (DR6) is abnormal in some cancer types, but the function and underlying molecular mechanisms of DR6 in tumor progression are not yet clear.
|
30186750 |
2018 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Death receptor 6 contributes to autoimmunity in lupus-prone mice.
|
28045014 |
2017 |
|
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
By employing promoter-linked reporter assay, we showed that HCV upregulated DR6 via ROS-mediated NF-κB pathway.
|
28743875 |
2017 |
|
Angioimmunoblastic Lymphadenopathy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
More importantly, we identified mutations in TNFRSF21 (1/9), CCND3 (1/9) and SAMSN1 (1/9), which are not yet seen or strongly implicated in the pathogenesis of AITL.
|
28148900 |
2017 |
|
Kidney Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, p53/miR-17-5p/DR6 is a new protective pathway in renal ischemia-reperfusion injury and may be targeted for the prevention and treatment of ischemic acute kidney injury.
|
27622990 |
2017 |
|
Malignant transformation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Mutations in RHOA, PLCG1 and TNFRSF21 (DR6), which encode proteins critical for T-cell biology, most likely promote T-cell differentiation and malignant transformation, consequently generating the malignant phenotype.
|
28148900 |
2017 |